Astel­las re­joins the au­toim­mune an­ti­body craze with Pan­dion part­ner­ship

Over a year ago, Astel­las CEO Ken­ji Ya­sukawa an­nounced a large R&D re­struc­ture: 600 cut jobs, mul­ti­ple re­search sub­sidiaries shut down, and a re­jig­gered ear­ly pipeline ap­proach cen­tered on so-called “fo­cus ar­eas.” Each fo­cus area was de­tailed briefly in a re­port they re­leased, along with how they’d reach the ther­a­py.

But one sub-fo­cus area looked dif­fer­ent. Rather than list the fea­tures of their tech­nol­o­gy, the space be­low au­to-an­ti­bod­ies (a form of au­toim­mune dis­or­der) said sim­ply “de­vel­op­ment of new plat­form.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN